

# Curriculum Vitae

Family name: Sabella

Given name: Giovanna

Gender: Female

Citizenship: Italian

## Qualifications

- 01/02/2022-current**      **Medical Pathologist, First Pathology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy**
- 02/01/2018-current**      **Resident in Pathology/ Pathology Fellow, School of Pathology, University of Milan, Milan, Italy, with six months rotation in the following scientific departments:**
- Human Pathology Unit, Department of Health Sciences, San Paolo Hospital, Milan, Italy
- Pathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy
- Inter-Hospital Pathology Division, IRCCS MultiMedica, Milan, Italy
- Division of Pathology, Ospedale Luigi Sacco-Fatebene Fratelli (FBF), Milan, Italy
- 10.04.2017**      Qualified to practice medicine. Board position: OMCeOLE N°8331
- 21.10.2016**      Doctor of Medicine, MD (Bachelor of Medicine, Bachelor of Surgery), School of Medicine, University Campus Biomedico of Rome (UCBM)  
Vote: 110/110 cum laude
- 2017-2015**      Internship in Pathology, University Campus Biomedico (UCBM), Roma, Italy

## Publications

Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach? (Cattaneo et al. Crit Rev Oncol Hematology 2023)

Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids (Centonze et al. Histopathology 2023)

Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge (Rossi RE. et al J Clinic Med 2023)

Loss of Primary Cilia Potentiates *BRAF/MAPK* Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (*CROCC*) Alterations (Remo A. et al. Genes (Basel) 2023)

Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin. (Ghelardi F et al. Clin Colorectal Cancer 2023)

Impact of Microscopically Positive ( $\leq 1$  mm) Distal Margins on Disease Recurrence in Rectal Cancer Treated by Neoadjuvant Chemoradiotherapy (Sorrentino et al. Cancers 2023)

Lung carcinoid tumours: histology and Ki-67, the eternal rivalry (Centonze et al. Histopathology 2023)

Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis (Centonze et al. Meta-Analysis Neuroendocrinology 2023)

FAP expression in alpha cells of Langherhans insulae-implications for FAPI radiopharmaceuticals' use (Kirienco et al. Eur J Nucl Med Mol Imaging 2023)

Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications (Simbolo et al. Cancers 2022)

Pathologic complete response after neoadjuvant chemotherapy/(re)chemoradiation for pelvic relapse of rectal cancer undergoing complex pelvic surgery: more frequent than expected? (Sorrentino et al. Int J. Colorectal Dis 2022)

Association of Upfront Peptide Receptor Radionuclide Therapy with Progression Free-Survival Among Patients with Enteropancreatic Neuroendocrine Tumors (Pusceddu et al. JAMA Netw Open 2022)

Low Baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict increased overall survival in locally recurrent rectal cancer despite R1 margins (Daveri et al. Dig Liver Dis 2022)

Colorectal medullary carcinoma: heterogeneous presentations of a rare clinico-pathological entity. Report of two cases (Romanzi et al. Tumori 2022)

BRAF-Mutated Colorectal adenocarcinomas: pathological heterogeneity and clinical implications (Angerilli et al. Crit Rev Oncol Hematol 2022)

Biomarker landscape in neuroendocrine tumors with high-grade features: current knowledge and future perspective (Prisciandaro et al. Front Oncol. 2022)

*COVID-19* Pandemic: huge stress test for health system could be a great opportunity to update the workflow in a modern surgical pathology (Belfiore et al. Cancers 2021)

Myeloid and T-Cell microenvironment immune features identify two prognostic sub-groups in high-grade gastroenteropancreatic neuroendocrine neoplasms (Centonze et. al J Clin Med 2021)

Parietal Pleura-based malignant perivascular epithelioid cell neoplasm protruding into serous cavity: A hitherto unrecognized occurrence (Pelosi et al. J Thorac Oncol 2020)

The conundrum of breast chondrolipoma: Heterotopic, metaplastic, or neoplastic lesion? (Sabella et. al Breast J 2019)

## Speakings

**24.06.2022**

Speaker at 4<sup>th</sup> Workshop of first division of Pathology of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano: 'Clinical predictivity of surgical Pathology'.

Scientific managers: Dr. Massimo Milione, Prof. Maurizio Colecchia

Four points by Sheraton Milan Center, Milan, Italy

- 02.05.2022** Scientific Training for Medical Affairs Team at Novartis on Neuroendocrine Neoplasms: 'The role of pathologist'
- 21.03.2022** Oral presentation of abstract titled: 'Ordinary Colorectal Carcinoma Expressing Synaptophysin OCCES: Clinicopathological prognostic factors and molecular features' at USCAP Annual Meeting 2022  
Los Angeles Convention Center, California, USA
- 24.09.2021**  
**04.02.2022** Case presentation at "Neuroendocrine neoplasms. Here the pathologist is at home!" Conference, two appointments.  
Moderators: Dr. Massimo Milione, Prof. Aldo Scarpa, Prof. Guido Rindi  
Starhotel E.c.ho. Milan, Italy

## Language Skills

Italian: Native

English: Full professional